Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus RENOVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus RENOVIST.
HYPAQUE SODIUM 20% vs RENOVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hypaque sodium is an ionic monomeric iodinated contrast medium that absorbs X-rays due to its iodine content, providing radiographic contrast. It increases the density of vascular structures and organ parenchyma, allowing visualization during imaging procedures.
RENOVIST is a radiocontrast agent that enhances imaging by attenuating X-rays due to its iodine content. It acts by increasing the density of blood vessels and tissues, improving contrast in radiographic studies.
Intravenous: 30-60 mL (6-12 g iodine) administered as a bolus or infusion for excretory urography; may be repeated up to a total of 125 mL (25 g iodine). Intra-arterial: Variable based on procedure, typically 8-30 mL for selective angiography.
0.5-1 mg/kg intravenously daily
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment.
Terminal half-life: 12 hours; in renal impairment (CrCl <30 mL/min) prolonged to 24-36 hours; dose adjustment required
Renal: >95% unchanged via glomerular filtration within 24 hours; <5% biliary/fecal.
Renal: 70% as unchanged drug; fecal: 20% as metabolites; biliary: 10%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent